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6March1958to28 November2015
Professor Henry Krum, a physician-scientist and world authority
on heart failure, best known for his innovation and leadership in
clinical trials, died on 28 November 2015 in Melbourne. He was
57. The cause of death was neuroendocrine cancer.
Krum was born in Melbourne, the son of Polish Jewish refugees
who fled the devastations of Europe after the Second World War.
While maintaining a life-long interest in journalism, Krum’s love of
science and medicine took prominence when he began studying
medicine at Melbourne University in 1976. Following his training
as a clinical pharmacologist and completing a PhD at the Austin
Hospital, Krum undertook a 2-year post-doctoral fellowship at
Columbia Presbyterian Medical Centre in New York under the
tutelage of Milton Packer before returning to Melbourne to launch
an independent academic career. Armed with new know-how on
the conduct of large-scale clinical trials in heart failure, Krum, in
a series of pivotal studies with international collaborators, began
helping to engineer the about-face in medical practice that turned
beta-blockers from contraindication to a fundamental tenet of
evidence-based practice.
Krum embraced the clinical trial process. He found enormous
satisfaction in being able to trump convention, myth, and wishful
thinking with fact, cherishing the international camaraderie engen-
dered by a common purpose of trying to improve the lot of those
living with heart failure. On the international steering committees
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.. of scores of clinical trials, it was hard to keep up with Krum’s trajec-
tory. Not a year went by without landmark publications in the top
tier of medical journals, the awarding of PhDs to new trainees in
heart failure research, continuing grant funding from the National
Health and Medical Research Council, and the immense productiv-
ity of the Monash Centre of Cardiovascular Research and Educa-
tion in Therapeutics that he founded and led. In 2014, he was cred-
ited by The Lancet, ‘to have put Australia on the map with respect
to clinical trials in cardiovascular disease, particularly in heart fail-
ure’. In August 2015, Krum was placed in Thomson Reuters Highly
Cited Researcher list, recognizing him as one of the world’s most
influential scientific minds with exceptional impact in his subject
field.
Refusing to be pigeon-holed as a purely clinical researcher, Krum
remained deeply committed to the process of discovery medicine,
maintaining his involvement in fundamental laboratory research
and co-founding a successful biotechnology company. Reflecting
the breadth of his understanding of the pathogenetic process, he
viewed the cardiac-centred view of heart failure as incomplete,
exploring, very much ahead of his time, its inter-relationship
with diabetes and kidney disease, the implications of which are
only now coming to be fully appreciated. For Krum, with his
background in studying the role of autonomic dysfunction in
blood pressure regulation, the implications of catheter-based renal
denervation were immediately apparent as he led the first major,
international proof-of-principle, safety and efficacy studies of this
new technology.
Though widely known for his medical research, Krum was a man
with diverse interests that included literature, film, sports, art, and
jazz. As with medicine, he pursued everything he did with fervent
passion. Seeing him stifle a yawn at work may have meant that
his flight from abroad had arrived earlier the same day or that his
slumber had been punctuated by a midnight teleconference with
the USA. It could, however, just as easily have meant a 3:00 am
soccer match, if his beloved Liverpool FC, ‘The Reds’, were playing.
Modest to the core, Krum downplayed his significant achieve-
ments, adopting a self-deprecating wit that would see him
comparing his life with a Woody Allen film or Seinfeld episode.
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Above all, Krum was a family man who never let his prolific work
life overshadow his commitment to his wife and two children.
In 2012, Krum was diagnosed with pancreatic neuroendocrine
cancer. Given a truly dismal prognosis by his treating oncologist,
Henry’s medical friends, following his example of challenging pre-
vailing norms, set about scouring the medical literature in search
of new potential treatments. As luck would have it, a major study
had just shown that the mTOR inhibitor, everolimus, significantly
prolonged progression-free survival among patients with advanced
disease. Though patients with high-grade tumours such as Krum
were not included in the trial, other studies indicated that such
malignancies continued to express mTOR abundantly. Accordingly, .
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. Krum’s medical friends reasoned that his cancer might also respond
to the treatment. So, Krum enjoyed a 2-year reprieve, during which
time he returned to business as usual; writing papers, speaking at
international conferences, applying for grants, and continuing in
his role as global PI and Executive Committee Chair of the 7000
patient ATMOSPHERE study of direct renin inhibition. It seemed
that nothing could stop this remarkable man until things took a
sharp turn for the worse in early 2015, when the cancer became
rampant.
Henry is survived by his wife of 26 years, artist, Lauren
Berkowitz, their two children, Joshua and Emily, and sister, Sharon,
a New York-based writer.
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